DETACT sEvere asThmAtiC paTients - a Pilot Study

Sponsor
Medical University of Vienna
Study ID
NCT07025200
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    Clinical assessment, lung function, CT-scans and Bronchoscopy prior to and 22 weeks after initiation of Dupilumab.

Study Details

The objective of this study is to investigate the effect of dupilumab treatment on mucus plugging in severe asthma patients with severe eosinophilic asthma. Therefore, the investigators plan to apply computer tomography to investigate mucus plugging and thoroughly examine different airway samples from Type 2-high severe asthmatic patients at a cellular, molecular, microbiological and metabolomic level. This study will help to unravel underlying treatment mechanisms of dupilumab therapy in severe asthmatics.

Key Dates

Start date
Feb 16, 2023
Status verified
Jun 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
10 participants (estimated)

Arms

  • Arm: Dupilumab treated patients
    All patients will be administered subcutaneous doses of dupilumab every 2 weeks.

Primary Outcome Measure

Effect of Dupilumab treatment on mucus plugging in patients with severe eosinophilic asthma [ Time Frame: 26 weeks ]

Central Contacts

Related Studies